Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01154933 · ClinicalTrials.gov registry record · Phase 2
Exeantide in Type 2 Diabetes on Insulin
A Phase 2 study, sponsored by University at Buffalo.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT01154933: Completed Phase 2 study, sponsored by University at Buffalo.
NCT01154933 is a Phase 2 study that has completed, run by University at Buffalo. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01154933, a Phase 2 study, has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
Exenatide has been shown to result in better glycemic control in type II diabetes patients. Obesity and diabetes are states of increased inflammation; exenatide is expected to lead to decreased inflammation by virtue of better glycemic control and weight loss. The purpose of this study is to determine if the addition of Exenatide to diabetic patients will reduce the requirements of insulin particularly the short acting insulin. Exenatide may also lead to decreased inflammation by virtue of better glycemic control and weight loss, or an independent effect.
Primary Outcome
To compare the fasting insulin level at the end of 12 weeks in patients on exenatide subcutaneously twice daily (5 or 10 mcg/injection) as compared to controls in insulin treated obese type 2 diabetic patients.
Interventions
- DRUG placebo
- DRUG exenatide 5 mcg
- DRUG exenatide 10 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-04 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
What the finished NCT01154933 record still lists
NCT01154933 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01154933 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01154933 about?
NCT01154933 is a clinical study titled "Exeantide in Type 2 Diabetes on Insulin". Exenatide has been shown to result in better glycemic control in type II diabetes patients. Obesity and diabetes are states of increased inflammation; exenatide is expected to lead to decreased inflammation by virtue of better glycemic control and weight loss. The purpose of this study is to determ...
What is the current status of trial NCT01154933?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2008-04. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01154933?
The interventions under investigation include: placebo (DRUG), exenatide 5 mcg (DRUG), exenatide 10 mcg (DRUG).
Who is sponsoring clinical trial NCT01154933?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01154933's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia